TRACON Pharmaceutical (TCON) – PRNewswire
-
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors
Back to TCON Stock Lookup
